Atezolizumab Plus Paclitaxel in Breast Cancer: FDA Issues Safety, Efficacy AlertSeptember 8th 2020
The FDA has issued an alert to professionals, investigators, and patients that the phase 3 IMpassion131 trial (NCT03125902) failed to show the effectiveness of atezolizumab (Tecentriq) plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.
FDA Update on Breast Implant-Associated Lymphoma, Breast Implant IllnessAugust 24th 2020
The Food and Drug Administration (FDA) provided an update on breast-implant associated side effects that have been reported to the agency, including breast implant-associated anaplastic large cell lymphoma (BI-ALCL) and symptoms that are commonly referred to by patients as breast implant illness (BII).
HER2+ Breast Cancer Treatment Continues to Change: Expert Weighs InAugust 20th 2020
The HER2-positive breast cancer treatment paradigm is constantly changing, explained Debu Tripathy, MD, who cited that in less than 1 year, there have been 2 exciting drug approvals, which are tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu).
Support Patients' Treatment Decisions During COVID-19August 9th 2020
Patients with breast cancer may be apprehensive to come into the clinic for treatment amidst the coronavirus disease 2019 (COVID-19) pandemic. However, others may prefer seeing their treatment team in person.
AE Management and Adherence Is Key in Breast Cancer TreatmentAugust 1st 2020
One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events (AEs) are properly managed—specifically in those patients with breast cancer, according to Patricia Jakel, RN, MN, AOCN.
F-627 Shows Strong, Beneficial for Chemotherapy-Induced Neutropenia in Breast CancerJuly 11th 2020
Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.
HER2+ Breast Cancer With Brain Metastases: Unmet Needs RemainJuly 7th 2020
Patients with metastatic HER2-positive breast cancer who later develop central nervous system (CNS) metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup, explained Brian Czerniecki, MD, PhD.
FDA Approves Phesgo, an In-Home Breast Cancer TreatmentJune 29th 2020
The FDA approved subcutaneous Phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase–zzxf – for the treatment of patients with metastatic HER2-positive breast cancer, as well as early-stage HER2-positive breast cancer, as selected by an FDA-approved companion diagnostic test.
PIK3A-Mutant Breast Cancer Shows Increased Sensitivity to PI3Kα InhibitionJune 27th 2020
Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.
Helping Breast Cancer Survivors Deal With Body Image IssuesJune 19th 2020
Your patient had a mastectomy and chemotherapy and is recovering on the post-op surgical oncology unit. She has 1 or 2 JPs (Jackson Pratt’s) which are drained on a prn basis and a surgical bra. The physical part of her recovery is in progress, but what about body image issues?
Expert Talks Immunotherapy for TNBC TreatmentMay 16th 2020
The addition of immunotherapy to the triple-negative breast cancer (TNBC) armamentarium has led to a paradigm shift and sparked an abundance of research with immuno-oncology (IO) drugs in new combinations and settings, explained Hope S. Rugo, MD.
Patient Education for Oral Therapies Is CrucialApril 29th 2020
There is far less patient education for oral agents, such as CDK4/6 inhibitors for breast cancer, as there is for chemotherapy. This is a major issue, explained Patricia Jakel, MN, RN, AOCN, advanced practice nurse at UCLA's solid tumor program and co-editor in chief of Oncology Nursing News.
Talazoparib Improves Quality of Life, Not Survival in Advanced Breast CancerApril 28th 2020
Treatment with talazoparib (Talzenna) did not demonstrate a statistically significant overall survival (OS) benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer, according to updated findings from the phase 3 EMBRACA trial (NCT01945775).1 However, lead author Jennifer Litton, MD, said that there is still reason to believe treatment with the PARP inhibitor can improve OS.
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast CancerApril 22nd 2020
The FDA has granted an accelerated approval to the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease.
FDA Approves Tucatinib to Treat HER2+ Breast CancerApril 17th 2020
The FDA has approved tucatinib (Tukysa) for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 1 prior therapy.
Indigenous American Ancestry May Be Associated With HER2+ Breast Cancer RiskApril 11th 2020
An increased proportion of Indigenous American (IA) genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer, according to findings from a study published in Cancer Research.
Making Cold Breast Cancer Tumors HotMarch 24th 2020
There are multiple factors in making "cold" breast cancer tumors "hot," meaning that they respond to chemotherapy, explained Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.